Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Diabetes in Control publishes complete list of drugs that affect blood glucose

Any clinician knows that there's a massive amount of new diabetes research and clinical information released daily, which makes keeping pace with best practices almost a full-time job.

20 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

ACE survey: 55% of patient with type 2 diabetes experience hypoglycemia

New survey data released today at the American Association of Clinical Endocrinologists 20th Annual Meeting and Clinical Congress reveal that more than half of people with type 2 diabetes across the country report they have experienced hypoglycemia, or low blood sugar.

15 Apr 2011

Medtronic introduces Enlite Sensor for continuous glucose monitoring

Medtronic, Inc. announces the launch of Enlite Sensor, the newest and most advanced glucose sensor for continuous glucose monitoring, in more than 35 countries outside of the United States.

12 Apr 2011

Refined carbohydrates create an ill and obese population

When it comes to feeding a body well, we've all been told we need proteins, fats and carbohydrates. For years, many of those we trust for health information have told us that the foundation of our diet should primarily consist of carbohydrates, namely, grains, breads and pastas.

8 Apr 2011

New medical guidelines for diabetes care

Today the American Association of Clinical Endocrinologists released new medical guidelines for developing comprehensive care plan for management of diabetes mellitus.

6 Apr 2011

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Over and under treatment of hyperglycemia in hospitalized patients leads to patient safety issues

The publication of the systematic review of intensive insulin therapy in hospitalized patients and the American College of Physicians (ACP) clinical guidelines for inpatient glucose control in the February 15th issue of Annals of Internal Medicine has again raised the issue of optimal management of hyperglycemia in the hospital.

17 Feb 2011

Impaired brain insulin action may worsen type 2 diabetes

Researchers from Mount Sinai School of Medicine have discovered a novel function of brain insulin, indicating that impaired brain insulin action may be the cause of the unrestrained lipolysis that initiates and worsens type 2 diabetes in humans. The research is published this month in the journal Cell Metabolism.

17 Feb 2011

Leading foundations support Australian diabetes treatment

Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US$140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that has the potential to transform the treatment of Type 1 diabetes.

15 Feb 2011

Researchers discover mechanism for normalizing blood sugar without insulin need

Diabetes can result from either a deficiency of insulin or decreased sensitivity to insulin. Researchers at Children's Hospital Boston have discovered a mechanism for normalizing blood sugar that doesn't involve insulin and could offer a new therapeutic approach to both kinds of diabetes.

14 Feb 2011

Despite fetal pulmonary maturity, babies delivered prior to 39 weeks are at risk

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that despite fetal pulmonary maturity, babies delivered at between 36 to 38 weeks, still have a significantly increased risk of neonatal morbidities.

11 Feb 2011

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.

10 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

InQ Biosciences, a provider of innovative technologies for cell growth and research, today announced that a pre-commercial version of its InQ Cell Research System is being utilized in a University of Alabama at Birmingham study evaluating the effects of secondary injury components on brain cells.

19 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011